Inhaled verapamil in patients with pulmonary hypertension secondary to chronic obstructive pulmonary disease (COPD)
A placebo controlled clinical trial on the efficacy of inhaled verapamil 10 mg stat administration in patients with chronic obstructive pulmonary disease (COPD) and pulmonary arterial pressure(PAP)>45 mmHg.
Shahid Beheshti University, M.C.
30 participants
Feb 27, 2012
Interventional
Conditions
Summary
We could not find any study that has examined the use of verapamil in PH secondary to COPD. The proposed study will provide scientifically valid data to date on whether nebulised verapamil (10 mg) is effective in these cases or not.
Eligibility
Inclusion Criteria1
- Patients with pulmonary arterial pressure (PAP)>45mmHg secondary to chronic obstructive pulmonary disease (COPD) and normal ejection fraction (EF) (> 40%).
Exclusion Criteria1
- Pregnancy 2.Patients with previous known hypersensitivity to verapamil (any formulation or route of administration) 3. Patients with sepsis 4. Patients with dysrythmia or heart block (second degree and third degree). 5.Patients with COPD exacerbation 6.Any contraindication for verapamil 7.Presence of an end stage disease (cardiac, renal and hepatic) 8.Patients receiving another calcium channel blocker (CCB), sildenafil and bosentan .
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
ARM 1:(a) Intervention group - nebulised verapamil ( 4ml,10mg) (the dosing form that exist in the market ,is 2.5 mg/ml as an injectable solution) once only. ARM 2:(b)Placebo group (4ml of distilled water) once only.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12612001239853